Results 11 to 20 of about 5,784 (166)

Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face [PDF]

Case Reports in Oncological Medicine, 2015
Background. For large basal cell carcinomas (BCCs) of the head and neck, definitive surgery often requires extensive resection and reconstruction that may result in prolonged recovery and limited cosmesis.
Alec M. Block, Fiori Alite, Aidnag Z. Diaz, Richard W. Borrowdale, Joseph I. Clark, Mehee Choi   +5 more
doaj   +2 more sources

Transformation of facial basal cell carcinoma to squamous cell carcinoma following vismodegib

Otolaryngology Case Reports, 2021
Objective(s): Vismodegib, a unique hedgehog pathway inhibitor, has been demonstrated to be effective in the treatment of non-operable and metastatic basal cell carcinoma (BCC).
Dustin A. Silverman, Michael M. Li, Thomas E. Olencki, Nolan B. Seim, Theodoros N. Teknos, Stephen Y. Kang   +5 more
doaj   +2 more sources

Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases

Plastic and Reconstructive Surgery, Global Open, 2017
Summary:. Basal cell carcinoma (BCC) is the most common periocular skin cancer and can lead to significant morbidity. We assess the effectiveness of vismodegib, a first-in-class Hedgehog signaling pathway inhibitor, in the management of periocular and ...
Kai Yuen Wong, MA, MRCS, Kate Fife, MD, FRCP, FRCR, John T. Lear, MD, FRCP, Richard D. Price, MD, FRCS (Plast), Amer J. Durrani, MSc, FRCS (Plast)   +4 more
doaj   +2 more sources

Wuguchong Bioactive Peptides Promote Wound Healing via Hedgehog Pathway‑Mediated Fibroblast Modulation. [PDF]

Chem Biodivers
The skin undertakes multiple critical physiological functions, including barrier protection and thermoregulation. However, chronic non‐healing ulcers have emerged as a major clinical challenge. In wound repair, skin healing is a highly coordinated, time‐sequential process wherein fibroblasts—key dermal cells—play irreplaceable roles in proliferation ...
Li K, Sun Y, Pang L, Gao T, Diao Y, Fan S.   +5 more
europepmc   +2 more sources

Vismodegib for periocular basal cell carcinoma: an international multicentre case series

, 2020
Introduction Vismodegib (Erivedge, Genentech) is a first-in-class inhibitor of the hedgehog (Hh) pathway, which is licensed for use in locally advanced basal cell carcinoma (BCC) and metastatic BCC.
Clarke, L., Cranstoun, M., Althaus, M., D. Morris, H. Oliphant, A. Haridas, P. Norris, S. N. Rajak, Sullivan, T. J., J. Laybourne, M. Cranstoun, Morris, D., L. Clarke, Norris, P., Chan, K., T. J. Sullivan, K. Chan, Rajak, S. N., Oliphant, H., Laybourne, J., M. R. Edmunds, M. Althaus, Haridas, A., Edmunds, M. R.   +23 more
core   +4 more sources

A Non-interventional Study on Vismodegib for Basal Cell Carcinoma With A Treat-To-Target Regimen In Swedish Patients

Dermatology Practical & Conceptual, 2023
Introduction: Real-life data on vismodegib in advanced basal cell carcinoma (aBCC) are limited. Optimal treatment duration is left to the discretion of the physician. Objectives: To assess the effectiveness, safety and treatment pattern for vismodegib
Niels Bendsöe, John Paoli, Karin Söderkvist, Bertil Persson, Christina Halldin, Linda Ihrlund, Maria Wolodarski   +6 more
doaj   +1 more source

The Topical Nanodelivery of Vismodegib Enhances Its Skin Penetration and Performance In Vitro While Reducing Its Toxicity In Vivo

Pharmaceutics, 2021
Vismodegib is a first-in-class inhibitor for advanced basal cell carcinoma treatment. Its daily oral doses present a high distribution volume and several side effects.
Maria Natalia Calienni, Daniela Maza Vega, C. Facundo Temprana, María Cecilia Izquierdo, David E. Ybarra, Ezequiel Bernabeu, Marcela Moretton, Fernando C. Alvira, Diego Chiappetta, Silvia del Valle Alonso, María Jimena Prieto, Jorge Montanari   +11 more
doaj   +1 more source

Mohs Surgery Outcomes for Basal Cell Carcinoma Treated With Neoadjuvant Sonic Hedgehog Inhibitor. [PDF]

Int J Dermatol
International Journal of Dermatology, Volume 65, Issue 7, Page 1493-1494, July 2026.
Barnawi G, Lazarowitz R, Aly S, Nukaly H, Weiss E.   +4 more
europepmc   +2 more sources

Low-Dose Vismodegib as Maintenance Therapy After Locally Advanced Basal Cell Carcinoma Complete Remission: High Efficacy with Minimal Toxicity

Dermatology and Therapy, 2020
Introduction Locally advanced basal cell carcinoma (laBCC) has always represented an uncommon, difficult-to-treat form of skin cancer, but approval of the Hedgehog inhibitor (HHI) vismodegib has provided an effective, well-tolerated therapy.
Massimiliano Scalvenzi, Milena Cappello, Claudia Costa, Gabriella Fabbrocini, Mariaantonietta Luciano, Alessia Villani   +5 more
doaj   +1 more source

Tolerance of sonidegib after intolerance of vismodegib—Experience in two patients with nevoid basal cell carcinoma syndrome (Gorlin syndrome)

Skin Health and Disease, 2023
Nevoid basal cell carcinoma syndrome (NBCCS, Gorlin syndrome) is a rare genetic condition characterized by the early development of numerous cutaneous basal cell carcinomas (BCCs).
Federico Venturi, Luciana Trane, Flavia Silvestri, Biancamaria Zuccaro, Elisabetta Magnaterra, Vincenzo De Giorgi   +5 more
doaj   +1 more source